A new study emphasizes the importance of considering sex differences in Alzheimer’s research – a step that could ultimately lead to more precise and effective treatments.
A powerful new analytical tool offers a closer look at how tumor cells “shape-shift” to become more aggressive and untreatable, as shown in a study from researchers at Weill Cornell Medicine and the New York Genome Center.
Thomas Ristenpart, a Professor at Cornell Tech and in the Computer Science Department at Cornell University, received the esteemed Test of Time Award at the 33rd USENIX Security Symposium. This accolade recognizes his co-authored…
As Cornell Tech looks toward future development, it aims to go beyond simply reducing its environmental impact. By continuing to innovate and incorporate new sustainable technologies, the New York City campus is a model for how…
A new preclinical model using CRISPR has given Weill Cornell Medicine researchers and their colleagues a deeper insight into how prostate cancer spreads or metastasizes.
A multi-institutional clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators showed that a newer technique for collecting prostate biopsy samples reduced the risk of infection compared with traditional biopsy approaches.
Immunocompromised people with persistent COVID infections can harbor drug-resistant variants of the virus, which have the potential to spread, researchers at Weill Cornell Medicine, the College of Veterinary Medicine and the NIH have found.
A new study from Weill Cornell Medicine researchers helps explain why having ApoE4 – the gene variant most closely linked to Alzheimer’s disease – increases the risk of neurodegeneration and white matter damage.
Taking race into account when developing tools to predict a patient’s risk of colorectal cancer leads to more accurate predictions when compared with race-blind algorithms, researchers find.
